Anja Bosler - Evotec SE Principal Accounting

All Insiders . USA . 
Stock . Evotec SE . Stakeholders . Insider . Anja Bosler
EVOTF Stock  USD 6.77  0.00  0.00%   

Insider

Anja Bosler is Principal Accounting of Evotec SE
Phone49 40 560 81 0
Webhttps://www.evotec.com

Evotec SE Management Efficiency

Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.
Evotec SE has accumulated 326.34 M in total debt with debt to equity ratio (D/E) of 0.38, which is about average as compared to similar companies. Evotec SE has a current ratio of 3.5, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evotec SE until it has trouble settling it off, either with new capital or with free cash flow. So, Evotec SE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evotec SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evotec to invest in growth at high rates of return. When we think about Evotec SE's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Richard MDCollegium Pharmaceutical
64
John MinardoIronwood Pharmaceuticals
48
Steven SullivanAvadel Pharmaceuticals PLC
59
III CPAPacira BioSciences,
61
Jordan MDAvadel Pharmaceuticals PLC
46
Floyd MDAlkermes Plc
87
Alex DasallaCollegium Pharmaceutical
N/A
Christopher CoughlinPrestige Brand Holdings
67
Jonathan MDPacira BioSciences,
49
ACGI BScHUTCHMED DRC
70
Jason RickardIronwood Pharmaceuticals
53
Eiry MDNeurocrine Biosciences
60
Daryl GauglerPacira BioSciences,
62
Jeffrey ZerilloPrestige Brand Holdings
63
Charles NixonHUTCHMED DRC
54
Christian PharmDAvadel Pharmaceuticals PLC
N/A
Richard KimAvadel Pharmaceuticals PLC
55
Adel MekhailPrestige Brand Holdings
63
Philip TerpolilliPrestige Brand Holdings
N/A
Jude OnyiaNeurocrine Biosciences
60
Damian FinioPhibro Animal Health
54
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people. Evotec SE [EVOTF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-0.16
Return On Asset-0.0012

Evotec SE Leadership Team

Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthias Evers, Chief Board
Volker Braun, VP ESG
Cord Dohrmann, Chief Scientific Officer and Member of Management Board
Enno Spillner, CFO, Member of the Management Board
Monika Conradt, Global HR
Gabriele Hansen, Vice President Corporate Communications & Investor Relations
Christian Dargel, EVP Compliance
MBA MBA, Chairman CEO
Craig Johnstone, COO, Member of the Management Board
Anja Bosler, Principal Accounting

Evotec Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.16
Return On Asset-0.0012
Profit Margin(0.26) %
Operating Margin(0.01) %
Current Valuation2.68 B
Shares Outstanding176.95 M
Shares Owned By Insiders9.86 %
Shares Owned By Institutions66.12 %
Price To Earning347.66 X
Price To Book2.28 X

Currently Active Assets on Macroaxis

ESRTEmpire State Realty
CCitigroup
CCitigroup
GOOGAlphabet Inc Class C
DDDupont De Nemours

Other Information on Investing in Evotec Pink Sheet

Evotec SE financial ratios help investors to determine whether Evotec Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evotec with respect to the benefits of owning Evotec SE security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY